The ExoDx™ Prostate Test
A standalone, exosome-based prostate cancer test delivering a unique data point to help guide the prostate biopsy decision. The ExoDx Prostate test has been included in the NCCN Guidelines since 2019 for early detection of prostate cancer. The ExoDx Prostate test is independent of PSA and other standard of care (SOC) information.
For TeleMedicine visits, check out the At-Home Collection Kit!
Assess prostate cancer risk
Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer
Precisely predictive, clinically convenient
Simple urine test, non-DRE, included in the NCCN guidelines to help guide your patient to biopsy decision
A new standard in prostate risk assessment
Clinical studies demonstrate the ExoDx Prostate test discriminates between high-grade and low-grade prostate cancer and benign disease
A treasure trove of RNA, DNA and protein
Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs
ExoDx™ Prostate Test For U.S. Veterans
The ExoDx Prostate test is now available to U.S. Veterans. The Veteran population has a two-fold increased risk of prostate cancer incidence compared to the general population but if detected early, prostate cancer is treatable. The ExoDx Prostate Test (EPI) provides actionable information that aids the prostate biopsy decision for men with PSA in the ‘gray zone’ of 2–10 ng/mL and is not dependent on other clinical risk factors. Learn more about the EPI test including a testimonial of how the ExoDx Prostate test helped a 61-year old man facing a prostate biopsy.
What's New
-
An Integrated Biomarker and MRI Risk Assessment Approach to Prostate Cancer Diagnosis
Prostate cancer guidelines seek to optimize diagnosis while minimizing over-diagnosis. This webinar explores integrating biomarkers like ExoDx Prostate Test with MRI imaging for better risk assessment in patients considering biopsy.
-
Prostate Cancer Diagnosis Made Easier: Urine Tests Explained by Dr. Jason Alter
Dr. Geo interviewed Dr. Jason Alter, the Head of Scientific Affairs at Exosome Diagnostics, regarding the effectiveness of urine tests for identifying prostate cancer. Dr. Alter, with extensive experience in Urologic Oncology testing, discussed the integration of urine tests and their potential impact on diagnosis and treatment decisions.
-
New Technologies for Prostate Screening
In this episode of BackTable Urology, Dr. Jose Silva interviews Dr. Ali Kasraeian, a private practice urologic oncologist in Jacksonville, about different techniques and research on prostate cancer screenings.
-
-
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 3 of 3
Part 3 of 3. Dr. Phranq Tamburri, N.M.D., presents on what makes the ExoDx Prostate Test unique as well as why liquid biomarkers are useful.
-
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 2 of 3
Part 2 of 3. Dr. Phranq Tamburri, N.M.D., explains more about PSA (Prostate Specific Antigen) and three factors in assessing prostate cancer.
-
Simple Non-Invasive Urine Test for Prostate Cancer Risk | Part 1 of 3
Dr. Phranq Tamburri, N.M.D., presents on pandemic-induced changes in prostate cancer screening, the significance of PSA assessment amidst evolving guidelines, and the benefits of analyzing 3 genes in the ExoDx Prostate Test.
-
-
Beyond PSA: Utility of a Urine Gene Expression Assay for Early Prostate Cancer Detection
In this webinar, Dr. John Smith and Dr. Albala explore the breakthrough ExoDx™ Prostate Test, a non-invasive risk assessment tool for prostate cancer. They discuss its accuracy and ability to guide treatment decisions, highlighting its potential to revolutionize prostate cancer management and improve patient outcomes through personalized medicine.
-
Taking Charge of Your Prostate Health: Download eBook Today.
-
Industry Workshop Exosome Diagnostics - New Innovations: Use of a liquid biomarker as a risk assessment tool for use in early detection of prostate cancer
-
-
Smarter Screening for Prostate Cancer: The Road Forward in 2021 with Dr. Matthew Cooperberg
-
Prostate Cancer Risk Assessment: Getting Beyond PSA With Dr. Sanoj Punnen
-
Entering the Chat Room of Cancer Cells - How They Talk and Why We Should Listen
-
-
Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study
-
ExoDx Prostate Test: Implications for Value-Based Care with Dr. Judd Moul
-
Medicare Issues Final Local Coverage Decision for Bio-Techne's ExoDx Prostate (Intelliscore) Test
-
-
ExoDx Prostate(IntelliScore) (EPI) Included in National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection
Stay in Touch with ExosomeDx
Join our Mailing LIstReceive updates and scientific advances
Partner with Exosome Diagnostics
Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".
Dr. Johan Skog is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael Valentino is Exosome Diagnostic's Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.
